Maris 23, 2023: Magungunan ƙwayoyin cutar kansa na farko da farkon matakan da Shanghai Biotech Oricell ke haɓaka sun sami ƙarin tallafin dala miliyan 45, in ji kamfanin a ranar Talata.
Bayan nuni a ASCO a bara tare da GPRC5D-directed CAR-T far don mahara myeloma, Oricell ya tara dala miliyan 120 Series B a watan Yuli. Sabbin masu saka hannun jari Qiming Venture Partners da C&D Emerging Industry Equity Investment tare da masu saka hannun jari na RTW Zuba Jari da Hukumar Zuba Jari ta Qatar ta jagoranci sabon haɓaka, wanda shine faɗaɗa wannan zagaye.
Kamfanin fasahar kere kere ya bayyana cewa sabbin kudaden da aka samu za a yi amfani da su ne da farko don bincike na asibiti a Amurka.
Oricell yana aiki akan adadin CAR-T hanyoyin kwantar da hankali da ƙwaƙƙwaran ƙwayar cuta antibody. Ƙungiyar marasa lafiya tare da maganin juriya Multi myeloma ya amsa wa Oricell's GPRC5D-directed CAR-T tare da ƙimar amsa gabaɗaya 100% da 60% cikakkiyar amsa a cikin gwajin Mataki na I wanda aka gabatar a ASCO.
Kuna so karanta: CAR T-Cell far a China
Musamman, Oricell ya haskaka ƙungiyar marasa lafiya biyar waɗanda suka riga sun karɓi BCMA CAR-T far. A cewar kamfanin, wani bangare na amsawa, "amsoshi masu kyau sosai" guda biyu, da kuma cikakkun amsa guda biyu duk an karɓi su. Kuma tare da tsaka-tsaki mai biyo baya daga kwanaki 35 zuwa 281, duk sun kasance marasa ci gaba a ranar yankewa a ASCO.
A cewar Oricell, wanda a halin yanzu yana cikin matakin ikon IND, yana fatan tsawaita gwajin don maganin CAR-T na GPRC5D zuwa Amurka.
Bugu da kari, Oricell yana da maganin tantanin halitta na CAR-T na GPC3 da ake kira Ori-C101, wanda yake karatu a cikin ci-gaban ciwon hanta.
CAR T-Cell far yana daga cikin hanyoyin magance wasu nau'ikan cututtukan daji na jini. Akwai fiye da 750 da ke gudana gwaji na asibiti a cikin CAR T-cell far a kasar Sin a halin yanzu. Marasa lafiya waɗanda ke son yin rajista za su iya tuntuɓar Faxar Cancer Layin taimakon marasa lafiya akan WhatsApp + 91 96 1588 1588 ko imel zuwa info@cancerfax.com.
